P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY

• Timothy Hughes,
• Delphine Rea,
• Carla Boquimpani,
• Yosuke Minami,
• Michael Mauro,
• Jorge Cortes,
• Jane Apperley,
• Valentin Garcia Gutierrez,
• Shruti Kapoor,
• Meryem Ktiouet-Dawson,
• Vishal Dhamal,
• Andreas Hochhaus

Affiliations

Timothy Hughes

1 SAHMRI (South Australian Health and Medical Research Institute), Adelaide, Australia

Delphine Rea

2 Hôpital Saint-Louis, Paris, France

Carla Boquimpani

3 HEMORIO, State Institute of Hematology Arthur de Siquiera Cavalcanti, Rio de Janeiro, Brazil

Yosuke Minami

4 National Cancer Center Hospital East, Kashiwa, Japan

Michael Mauro

5 Memorial Sloan Kettering Cancer Center New York, New York, United States

Jorge Cortes

6 Georgia Cancer Center, Augusta, United States

Jane Apperley

7 Centre for Haematology Imperial College London, London, United Kingdom

Valentin Garcia Gutierrez

8 Servicio de Hematología, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain

Shruti Kapoor

9 Novartis Pharmaceuticals Corporation, East Hanover, United States

Meryem Ktiouet-Dawson

10 Novartis Pharma AG, Basal, Switzerland

Vishal Dhamal

11 Novartis Healthcare Private Limited, Hyderabad, India

Andreas Hochhaus

12 Universitätsklinikum Jena, Jena, Germany